CD274 and cervical cancer: In 2020, Tamura et al. reported similar results for the use of nivolumab monotherapy in advanced or recurrent cervical cancer with an ORR of 33% [80%-CI: 17–53] in PD-L1 positive patients (n = 15) compared to 0% [80%-CI 0–37] in PD-L1 negative patients (n = 5).